IL13 and Alzheimer disease: Each patient with severe AD received treatment with dupilumab, a monoclonal antibody that blocks IL-4/IL-13 signaling, thereby inhibiting receptor signaling downstream in T cells; these patients exhibited huge decreases in EASI scores.